Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.

Autor: Tepler, Isidore, Schwartz, Gary, Parker, Karen, Charette, Jane, Kadin, Marshall E., Woodworth, Thasia G., Schnipper, Lowell E., Tepler, I, Schwartz, G, Parker, K, Charette, J, Kadin, M E, Woodworth, T G, Schnipper, L E
Zdroj: Cancer (0008543X); Feb1994, Vol. 73 Issue 4, p1276-1285, 10p
Databáze: Complementary Index
Externí odkaz: